CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study
- Sponsor
- Huazhong University of Science and Technology
- Study ID
- NCT07106411
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Leiomyoma
- Submucosal Tumor
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- Endoscopic Ultrasound — DIAGNOSTIC_TESTConventional EUS will be performed to evaluate lesion size, echogenicity, border, and layer of origin for differentiation between GISTs and leiomyomas and risk stratification of GISTs.
- Contrast-Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS) — DIAGNOSTIC_TESTCEH-EUS will be conducted using a contrast agent to assess vascularity and enhancement patterns of the lesion for differentiation between GISTs and leiomyomas and risk stratification of GISTs.
Study Details
The investigators conduct a prospective, multicenter diagnostic trial primarily aimed at evaluating the value of contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS) in differentiating gastrointestinal stromal tumors (GISTs) from leiomyomas, as well as its predictive utility in the risk stratification of GISTs.
Key Dates
- Start date
- Aug 31, 2025
- Status verified
- Jul 2025
- Primary completion
- Jun 30, 2026
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 288 participants (estimated)
Arms
- Arm: All ParticipantsAll enrolled patients with upper gastrointestinal subepithelial lesions confirmed by histopathology. Each participant underwent both endoscopic ultrasound (EUS) and contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) examinations.
Primary Outcome Measure
Diagnostic accuracy of CE-EUS and EUS for differentiating GIST from leiomyoma [ Time Frame: Within 1 month after final histopathological diagnosis ]
Central Contacts
- Bin Cheng13986097542
Related Studies
- Clinical & Pathological Studies of Upper Gastrointestinal CarcinomaRecruiting · Stanford University · Stanford, California
- Effects of Simvastatin on Uterine Leiomyoma SizePHASE2 · Recruiting · Johns Hopkins University · Baltimore, Maryland
- Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic AnalysisRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsPHASE1 · Recruiting · IDRX, Inc., a wholly owned subsidiary of GSK, LLC · Miami, Florida